Rapidx Pathology Labs: Financial Breakdown
Decoding financial health metrics of Rapidx Pathology Labs
Total Revenue₹9.7 Cr613%Prev. FY
Total Expenses₹9.3 Cr429%Prev. FY
Profit After Tax₹39.9 Lakh172%Prev. FY
Total Assets₹4.3 Cr331%Prev. FY
Net Profit Margin4.1%110%Prev. FY
FAQs on Financials of Rapidx Pathology Labs
Yes. In FY21, Rapidx Pathology Labs reported a profit after tax of ₹39.9 Lakh, making it profitable.
Rapidx Pathology Labs's revenue grew 613.4% year-on-year, from ₹1.4 Cr in FY20 to ₹9.7 Cr in FY21.
Rapidx Pathology Labs's estimated EBITDA for FY21 was ₹60.6 Lakh, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY21, Rapidx Pathology Labs posted revenue of ₹9.7 Cr (up 613.4% YoY) and a profit after tax of ₹39.9 Lakh. Explore the full financials of Rapidx Pathology Labs here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links